Joaquin Duato, J&J CEO (David Zorrakino/Europa Press via Getty Images)
October 19, 2023 11:10 AM EDTUpdated October 24, 03:44 AM
Cell/Gene Tx
Manufacturing

Up­dat­ed: J&J builds out glob­al man­u­fac­tur­ing ca­pac­i­ty for CAR-T Carvyk­ti

Anna Brown

News Reporter

John­son & John­son is ramp­ing up man­u­fac­tur­ing ca­pac­i­ty for the CAR-T ther­a­py it de­vel­oped with Leg­end Biotech, dri­ven by high de­mand for the Carvyk­ti, ex­ec­u­tives …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times